Hephaistos-Pharma, Liège (BE)

https://www.hephaistos-pharma.com

HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of immunostimulants against cancer, revolutionizing immune stimulation targeting TLR4 with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. HEPHAISTOS-Pharma is the laureate of prestigious grants such as BPIFRANCE i-Nov. In 2023, HEPHAISTOS was awarded a 2.5M€ EIC accelerator grant in Europe and is also part of the SyStInn consortium headed by academic partners that received a 9M€ RHU grant from the French National Research Agency, which will part-fund clinical trials on ONCO-Boost. HEPHAISTOS-Pharma is also one of the few innovative companies to be selected for its disruptive potential and supported by the Paris Saclay Cancer Cluster. HEPHAISTOS-Pharma is headquartered in France, with a subsidiary in Lie`ge, Belgium. *

	Start	2024-01-23 established (approx)
	Group	Hephaistos-Pharma (Group)
	Today	Hephaistos-Pharma (Group)
	Industry	cancer drug
	Industry 2	Onco-Boost

	Region	Liège (Lüttich)
	Country	Belgium
	City	n. a. Liège
		Address record changed: 2024-07-15

Basic data	Employees	n. a.

		* Document for »About Section«: Hephaistos-Pharma SAS. (1/23/24). "Press Release: Hephaistos-Pharma Secures a €2 Million Seed Round with Xista Science Ventures, Foundation Fournier-Majoie and Noshaq". Orsay.

		Record changed: 2025-03-16